Effect of Unani Medicine in Intellectual Deficit in Stroke Patients

Efficacy of Waj in post-stroke cognitive impairment: A Randomized Placebo Controlled Trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/068413

Enrollment

Registered

2024-06-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F70-F79- Intellectual disabilities

Interventions

Intervention1: Waj: 3gm of Waj will be given in capsule form daily in 2 divided doses for 6 weeks, each capsule will contain 750 mg of waj Control Intervention1: Placebo: Placebo (wheat flour) 3gm wil

Eligibility

Inclusion criteria

Inclusion criteria: 1)Age ranges from 30 to 75 years (30 and 75 also included), no gender limitation. 2)The presence of cognitive impairments (Montreal Cognitive Assessment, MoCA less than 26). 3)Patients having single ischaemic or haemorrhagic stroke documented by cerebral CT scanning or MRI before enrolment. 4)Patients having history of stroke more than 6 weeks. 5)No severe aphasia and able to accomplish cognitive tests. 6)Stable vitals, no progression of neurological symptoms. 7) Normal cognitive function before stroke. 8)Voluntary participation and signing the informed consent. 9)Educational level should be primary school or above, with the capability of finishing cognitive tests.

Exclusion criteria

Exclusion criteria: 1)Patients with pre stroke cognitive impairment. 2)Any neuropsychiatric comorbidity and affective disorder that could influence the test outcomes. 3)Patients with uncorrectable visual or hearing disturbances severe enough to preclude cognitive tests. 4)History of transcranial surgery or skull defect 5)Previous history of more than one episode of stroke. 6)Severe Aphasia. 7)Chronic Alcoholism. 8)Uncontrolled hypertension and Diabetes mellitus. 9)A medical condition that, in the investigator opinion, would interfere with treatment, safety, or adherence to the protocol.

Design outcomes

Primary

Measure	Time frame
• Improvement in Montreal Cognitive Assessment (MoCA) to evaluate the general cognitive functionTimepoint: 0, 14th, 28th, and 42nd day	—

Secondary

Measure	Time frame
• Improvement in Activities of Daily Living (ADL) assessed with the Barthel Index (BI)Timepoint: 0,and 42nd day	—

Countries

India

Contacts

Public ContactDr Muzafar Din Ahmad Bhat

National institute of unani medicine, Kottigepalya, Magadi main road Bangalore KARNATAKA

drmuzaffar79@gmail.com9590366192

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026